Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial
Open Access
- 30 October 2019
- journal article
- research article
- Published by Springer Nature in Respiratory Research
- Vol. 20 (1) , 1-15
Abstract
Background: Prospective evidence is lacking regarding incremental benefits of long-acting dual- versus mono-bronchodilation in improving symptoms and preventing short-term disease worsening/treatment failure in low exacerbation risk patients with chronic obstructive pulmonary disease (COPD) not receiving inhaled corticosteroids. Methods: The 24-week, double-blind, double-dummy, parallel-group Early MAXimisation of bronchodilation for improving COPD stability (EMAX) trial randomised patients at low exacerbation risk not receiving inhaled corticosteroids, to umeclidinium/vilanterol 62.5/25 μg once-daily, umeclidinium 62.5 μg once-daily or salmeterol 50 μg twice-daily. The primary endpoint was trough forced expiratory volume in 1 s (FEV1) at Week 24. The study was also powered for the secondary endpoint of Transition Dyspnoea Index at Week 24. Other efficacy assessments included spirometry, symptoms, heath status and short-term disease worsening measured by the composite endpoint of clinically important deterioration using three definitions. Results: Change from baseline in trough FEV1 at Week 24 was 66 mL (95% confidence interval [CI]: 43, 89) and 141 mL (95% CI: 118, 164) greater with umeclidinium/vilanterol versus umeclidinium and salmeterol, respectively (both p < 0.001). Umeclidinium/vilanterol demonstrated consistent improvements in Transition Dyspnoea Index versus both monotherapies at Week 24 (vs umeclidinium: 0.37 [95% CI: 0.06, 0.68], p = 0.018; vs salmeterol: 0.45 [95% CI: 0.15, 0.76], p = 0.004) and all other symptom measures at all time points. Regardless of the clinically important deterioration definition considered, umeclidinium/vilanterol significantly reduced the risk of a first clinically important deterioration compared with umeclidinium (by 16–25% [p < 0.01]) and salmeterol (by 26–41% [p < 0.001]). Safety profiles were similar between treatments. Conclusions: Umeclidinium/vilanterol consistently provides early and sustained improvements in lung function and symptoms and reduces the risk of deterioration/treatment failure versus umeclidinium or salmeterol in symptomatic patients with low exacerbation risk not receiving inhaled corticosteroids. These findings suggest a potential for early use of dual bronchodilators to help optimise therapy in this patient group.Keywords
Funding Information
- GlaxoSmithKline
This publication has 29 references indexed in Scilit:
- Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trialsThe Lancet Respiratory Medicine, 2014
- Once-Daily Umeclidinium/Vilanterol 125/25 μg Therapy in COPDChest, 2014
- Minimum clinically important difference for the COPD Assessment Test: a prospective analysisThe Lancet Respiratory Medicine, 2014
- Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPDRespiratory Medicine, 2013
- Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohortEuropean Respiratory Journal, 2013
- Dual bronchodilation with QVA149versussingle bronchodilator therapy: the SHINE studyEuropean Respiratory Journal, 2013
- Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group studyThe Lancet Respiratory Medicine, 2013
- Usefulness of the Chronic Obstructive Pulmonary Disease Assessment Test to Evaluate Severity of COPD ExacerbationsAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Disease severity and symptoms among patients receiving monotherapy for COPDPrimary Care Respiratory Journal, 2010
- Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2007